Our study supports the existing perception that β-lap is an NQO1 bioactivatable drug, and β-lap’s lethality stems from β-lap-induced futile redox cycling in NQO1+ cancer cells, producing oxidative DNA lesions and consequent PARP1- mediated necrotic cell death. The gene discussed is PARP1; the disease is cancer.